CEFALY Technology will introduce the first line treatment for migraine prevention at KIMES 2017 which will be held from March 16th to 19th at COEX.
CEFALY Technology is a Belgium-based company that has been set up in 2004. Its mission is to research and develop practical innovations for use on human in the field of electronics and bioelectronics. A skilled team of engineers and physicians rationalise and simplify sophisticated medical technologies to create simple systems that improve human health.
CEFALY Technology has developed a treatment for migraine prevention so called Cefaly. Cefaly is the first external cranial neurostimulation device for prevention of migraine. The Cefaly is applied to the forehead using a self-adhesive electrode positioned bilaterally over the upper branches of the trigeminal nerve which is involved in migraine mechanism. The Cefaly generates very precise electrical impulses allowing to stimulate the trigeminal nerve. Evidence-based Cefaly has the best safety/efficacy ratio in comparison with other treatments making. Cefaly a first choice for migraine patients.
Cefaly bears the CE Medical mark, is certified to the ISO Medical standard and approved by the FDA, CFDA, and registered by Korean FDA. The Cefaly will be exhibited at booth n° B127 for the first time at KIMES in Seoul from March 16th to 19th 2017 at COEX exhibition center in Seoul.
Meanwhile, KIMES 2017 is the biggest international medical and hospital equipment exhibition of Korea. KIMES sets the stage for introduction of latest tools and technology that may aid in the healthcare industry etc. in the Hospitals and Medical Equipments industry.
→ Go to 'KIMES 2017' News Page